NEPIC Innovation Day, November 15th 2011 Centre of Excellence in Biopharmaceuticals (CoEBP) Alan Dickson The University of Manchester Background: Science Need CoEBP CoEBP: What can we do Success to date Future plans Contacting us Source Evaluate Pharma 2010 Science Need Predicted Top Ten Therapeutics for 2016 Rank Product Company(s) Technology 2009 ($bn) 2016 ($bn) 1 Humira Abbott Laboratories/Eisai 5.6 10.1 2 Avastin Roche 5.7 8.9 3 Enbrel Amgen/Pfizer/Takeda 6.5 7.3 4 Rituxan Roche/Biogen Idec 5.6 6.8 5 Crestor AstraZeneca Shionogi Chiesi 4.8 6.3 6 Herceptin Roche 4.9 6.2 7 Remicade Johnson & Johnson Merck & Co Mitsubishi Tanabe 5.9 5.7 8 Lantus Sanofi-Aventis 4.3 5.3 9 Advair/Sereti GlaxoSmithKline/Almirall/Others de Prolia Amgen/Daiichi Sankyo/ GlaxoSmithKline Monoclonal antibody Monoclonal antibody Recombinant Product Monoclonal antibody Small molecule chemistry Monoclonal antibody Monoclonal antibody Recombinant product Small molecule chemistry Monoclonal antibody 8.0 5.2 0 5.2 10 Source Evaluate Pharma 2010 Science Need Transcription RNA processing Translation Secretion Amount Quality Purity Properties Bioprocessing Science Need Bioprocess – biopharmaceuticals, biologics Bioprocess - activities that enable design, development and production of biological medicines both in bulk and final dosage form Includes • Cell line development and cell banking, • Fermentation processes, • Recovery and purification processes, • Chemical modification, • Formulation process and dosage form, • Storage and stability, • Analytical methods, • Final product and stability testing Science Need Biopharmaceuticals: Current commercial reality 58 new biopharms products approved 2006-2010 32 – Chinese hamster ovary (CHO) cell 17 – E.coli 4 - S. cerevisiae 2 - Transgenic animals 2 - Insect cells 1 - Pichia pastoris (GlycoFi) Walsh, G [2010] Nature Biotechnology 28: 917-924 Science Need Immunoglobulin structure Commercially valuable Complex – IgG 150,000Da Aspirin 180Da Possible modifications 100 Billion combinations Functional quality R. Jefferis (2006) Nature Biotech. 24: 1230-1231 Structure generated by Peter Artymiuk (University of Sheffield, Sheffield, UK) using PyMOL (http://pymol.sourceforge.net/). Science Need The challenge of “improved” products -The complexity of the biological system Antibody (mAb) Fab scFv scAb Science Need The Biopharmaceuticals “pipeline”/system Required product (vs target) Expression system Helping with industrial challenges Scale-up and quantity Downstream processing/purification Formulation/storage Patient delivery The CoEBP Centre of Excellence in Biopharmaceuticals (COEBP) A short history • BIGT Report 2003 – maintaining UK position/investment • bioProcess UK (KTN) 2005 – industry/BRIC funding (£13M) • bioProcess UK 2006 – call for new Centres (especially training) • BRIC funding 2006/7– 19 companies/24 academic projects • Potential new Centres “anointed” 2007 – support (non-financial) • COEBP and NWDA 2007 onwards – application(s) from UoM • COEBP and ERDF/NWDA 2009 – application funded Oct 2009 • BRIC2 2010 – evolving industry funding route (£10M) • COEBP 2010 - staff appointments May 2009 • COEBP 2010 – robotics facility complete December 2010 The CoEBP Discovery Target identification Lead identification Lead optimisation Development Manufacturing Pharmaceutics Formulation/delivery Pre-clinical Clinical Toxicology Commercial Marketing/sales Manufacturing Supply chain Pharmaco-vigilance Discovery Bioprocessing* Formulation* Delivery* Toxicology* Clinical Research Diagnostics The CoEBP Centre of Excellence in Biopharmaceuticals (COEBP) Key activities: • Direct Business Support • Academic/industrial research collaborations • Exchange placements – industry/academia • Work-based Training • Establishment of Robotics capability TAP Thermo “New academic involvement” - engagement of “naïve” academics with the biopharms sector -application of new technologies and approaches to the sector What can we do? Pharmacy/ formulation, delivery Systems biology Structural biology Cell and molecular biology CoEBP Computational biology Physical sciences/ mathematics Toxicology/ immunogenicity Chemical engineering Analytical scientists What can we do? Knowledge transfer/ training activities Advisory services to the sector CoEBP Direct industry funded research (project/PhD) Industry advisory consultancies Contract services Research Funding (underpinning) Collaborative industry research (project/PhD) What can we do? Sonata – Protein Expression Automation Accelerating development of Biopharmaceuticals Mammalian Suspension Cell Culture Biologics Process Development − Culture Optimisation − Stability Studies − Scale-up Research & Drug Discovery − Protein Reagent Supply What can we do? Thermo Fisher Momentum F5 Accelerating development of Biopharmaceuticals Complete processing microtitre plates - High throughput capability - High content capability - Automated cell/reagent dispensing Assay and screening automation - Cellomics Arrayscan - Imaging of individual cells - Automated data handling and storage Success to date 17 Internal research programmes undertaken – 12 completed and some form grant applications, 5 on-going) 5 Research Council Project grants (£2.1M) 7 externally-funded PhD studentships 21 “Core” Academics 40+ 2° Academics Grant applications >£12M under consideration 6 Industrial group PhDs under discussion External Engagement 30 UK-based companies (14SMEs, 16 LOs) 5 EU/USA-based (1 SME, 4 Los) 3 directly-funded research contracts 5 programmes under discussion (2 technology evaluations) (3 research collaborations) Seminars and training modules (Aggregation, Systems Biology, Analytics) Advisory roles in consultancies and advisory committees Success to date Best? Growth rate, IVC,Qp, PTM and secretion, selective product handling, feed response Find the best cell (clone)? Success to date CHO clone selection – GFP cherry picking ThermoFisher System Success to date CHO Cell line (in)stability Specific productivity Cell growth Generation time Sonata TAP System Success to date Primary Neurone Screening ThermoFisher System Future plans Knowledge-based BioEconomy Research Vision Industrial Biotechnology - Bioprocessing - Funding bodies priorities - Strategic challenge UoM Long-term academic research funding – recruitment Short-/medium term industrial exchange/training Increased SME networking Increased generic training Contacting us http://www.coebp.ls.manchester.ac.uk University of Manchester Centre of Excellence in Biopharmaceuticals Professor David Clarke Dr Simon Merrywest Dr Joanne Flannelly Dr Annes Lambert Professor Ian Kimber Professor Pedro Mendes Dr Aline Miller Ms Rachel Ashworth Dr Malcolm Rhodes Professor Mike Sutcliffe Dr Egor Zindy COEBP Scientific Advisory Board Dr Kevin Cox Dr Geoff Davison Prof Douglas Kell Dr Mark Douglas Dr Ian Madley Dr Linda Magee Dr Daniel Smith The Dickson lab group and funders BBSRC BRIC (BBSRC/EPSRC/Industry) GlaxoSmithKline Life Technologies Lonza Biologics MedImmune (CAT) Pall Pfizer RecipharmCobraBiologics UCB Celltech